Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction

被引：18

作者：

Li, Junmin ^{[1
]}

Zhu, Hongming ^{[1
]}

Hu, Jiong ^{[1
]}

Mi, Jianqing ^{[1
]}

Chen, Saijuan ^{[1
]}

Chen, Zhu ^{[1
]}

Wang, Zhenyi ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Hematol, Rui Jin Hosp, Shanghai 200030, Peoples R China

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2014年 / 100卷 / 01期

关键词：

Acute promyelocytic leukemia; All-trans retinoic acid; Arsenic trioxide; Optimization therapy; TRANS-RETINOIC ACID; AGENT ARSENIC TRIOXIDE; RISK-ADAPTED TREATMENT; EARLY DEATH RATE; TERM-FOLLOW-UP; SINGLE-AGENT; ANTHRACYCLINE MONOCHEMOTHERAPY; CONSOLIDATION THERAPY; GEMTUZUMAB-OZOGAMICIN; CELL TRANSPLANTATION;

D O I：

10.1007/s12185-014-1603-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The past three decades have witnessed a great progress in the treatment of acute promyelocytic leukemia (APL). The current application of all-trans retinoic acid, arsenic trioxide (ATO), and anthracycline-based chemotherapies has been proved to be highly effective. Based on the risk factors of APL, optimization of the treatment emphasizes the role of ATO in induction, consolidation and maintenance therapy as a substitute to chemotherapy in low-and intermediate-risk patients, and in potential reduction of chemotherapy in high-risk group without impact on the outcome. However, early death and relapse remain obstacles to further improvement of the rates of remission and long-term survival, and the acute and chronic adverse effects of ATO should be considered for more appropriate management. Efforts should be made to more rationally obtain improved outcomes through the use of less toxic regimens.

引用

页码：38 / 50

页数：13

共 81 条

[31] Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia [J].

Hu, Jiong ;

Liu, Yuan-Fang ;

Wu, Chuan-Feng ;

Xu, Fang ;

Shen, Zhi-Xiang ;

Zhu, Yong-Mei ;

Li, Jun-Min ;

Tang, Wei ;

Zhao, Wei-Li ;

Wu, Wen ;

Sun, Hui-Ping ;

Chen, Qiu-Sheng ;

Chen, Bing ;

Zhou, Guang-Biao ;

Zelent, Arthur ;

Waxman, Samuel ;

Wang, Zhen-Yi ;

Chen, Sai-Juan ;

Chen, Zhu .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (09) :3342-3347

[32] USE OF ALL-TRANS RETINOIC ACID IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA [J].

HUANG, ME ;

YE, YC ;

CHEN, SR ;

CHAI, JR ;

LU, JX ;

ZHOA, L ;

GU, LJ ;

WANG, ZY .

BLOOD, 1988, 72 (02) :567-572

[33] All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4) [J].

Iland, Harry J. ;

Bradstock, Ken ;

Supple, Shane G. ;

Catalano, Alberto ;

Collins, Marnie ;

Hertzberg, Mark ;

Browett, Peter ;

Grigg, Andrew ;

Firkin, Frank ;

Hugman, Amanda ;

Reynolds, John ;

Di Iulio, Juliana ;

Tiley, Campbell ;

Taylor, Kerry ;

Filshie, Robin ;

Seldon, Michael ;

Taper, John ;

Szer, Jeff ;

Moore, John ;

Bashford, John ;

Seymour, John F. .

BLOOD, 2012, 120 (08) :1570-1580

[34] Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia [J].

Ito, S ;

Ishida, Y ;

Oyake, T ;

Satoh, M ;

Aoki, Y ;

Kowata, S ;

Uchiyama, T ;

Enomoto, S ;

Sugawara, T ;

Numaoka, H ;

Suzuki, K ;

Murai, K .

LEUKEMIA & LYMPHOMA, 2004, 45 (09) :1783-1789

[35] Arsenic: toxicity, oxidative stress and human disease [J].

Jomova, K. ;

Jenisova, Z. ;

Feszterova, M. ;

Baros, S. ;

Liska, J. ;

Hudecova, D. ;

Rhodes, C. J. ;

Valko, M. .

JOURNAL OF APPLIED TOXICOLOGY, 2011, 31 (02) :95-107

[36] Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia [J].

Kim, Dae-Young ;

Lee, Je-Hwan ;

Lee, Jung-Hee ;

Kim, Sung-Doo ;

Lim, Sung-Nam ;

Choi, Yunsuk ;

Lee, Young-Shin ;

Kang, Young-Ah ;

Seol, Miee ;

Jeon, Mijin ;

Kim, Joo Youn ;

Lee, Kyung-Hwa ;

Lee, Yeon-Joo ;

Lee, Kyoo-Hyung .

LEUKEMIA RESEARCH, 2011, 35 (02) :152-158

[37] Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry [J].

Lehmann, S. ;

Ravn, A. ;

Carlsson, L. ;

Antunovic, P. ;

Deneberg, S. ;

Mollgard, L. ;

Derolf, A. Rangert ;

Stockelberg, D. ;

Tidefelt, U. ;

Wahlin, A. ;

Wennstrom, L. ;

Hoglund, M. ;

Juliusson, G. .

LEUKEMIA, 2011, 25 (07) :1128-1134

[38] Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia [J].

Lengfelder, E. ;

Hofmann, W-K ;

Nowak, D. .

LEUKEMIA, 2012, 26 (03) :433-442

[39] Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia [J].

Lo-Coco, F ;

Cimino, G ;

Breccia, M ;

Noguera, NI ;

Diverio, D ;

Finolezzi, E ;

Pogliani, EM ;

Di Bona, E ;

Micalizzi, C ;

Kropp, M ;

Venditti, A ;

Tafuri, A ;

Mandelli, F .

BLOOD, 2004, 104 (07) :1995-1999

[40] Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia [J].

Lo-Coco, F. ;

Avvisati, G. ;

Vignetti, M. ;

Thiede, C. ;

Orlando, S. M. ;

Iacobelli, S. ;

Ferrara, F. ;

Fazi, P. ;

Cicconi, L. ;

Di Bona, E. ;

Specchia, G. ;

Sica, S. ;

Divona, M. ;

Levis, A. ;

Fiedler, W. ;

Cerqui, E. ;

Breccia, M. ;

Fioritoni, G. ;

Salih, H. R. ;

Cazzola, M. ;

Melillo, L. ;

Carella, A. M. ;

Brandts, C. H. ;

Morra, E. ;

von Lilienfeld-Toal, M. ;

Hertenstein, B. ;

Wattad, M. ;

Luebbert, M. ;

Haenel, M. ;

Schmitz, N. ;

Link, H. ;

Kropp, M. G. ;

Rambaldi, A. ;

La Nasa, G. ;

Luppi, M. ;

Ciceri, F. ;

Finizio, O. ;

Venditti, A. ;

Fabbiano, F. ;

Doehner, K. ;

Sauer, M. ;

Ganser, A. ;

Amadori, S. ;

Mandelli, F. ;

Doehner, H. ;

Ehninger, G. ;

Schlenk, R. F. ;

Platzbecker, U. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) :111-121

← 1 2 3 4 5 6 7 8 9 →